Interactive Brokers shares jump as it secures spot in S&P 500
Capricor Therapeutics, Inc. (NASDAQ:CAPR), currently valued at $468.5 million, disclosed in a recent SEC filing that its stockholders have approved the adoption of the Capricor Therapeutics 2025 Equity Incentive Plan during the Annual Meeting held on Thursday. The newly adopted plan will reserve 3.5 million shares of common stock for equity-based awards to employees, directors, and consultants. According to InvestingPro analysis, the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 6.55x, suggesting ample liquidity to support its compensation initiatives.
The plan, which was initially approved by the Board of Directors subject to stockholder approval, will also see an automatic increase in the number of shares authorized for issuance under the plan. Starting January 1, 2026, and on the first day of each year until January 1, 2035, the number of shares will increase by 5% of the outstanding shares as of the end of the prior fiscal year. This comes as the stock has shown mixed performance, with a strong 71% return over the past year despite a recent 46% decline over the last six months.
The Annual Meeting, which took place at the company’s headquarters in San Diego, California, also included the election of eight directors to serve until the 2026 annual meeting, the ratification of Rose, Snyder & Jacobs LLP as independent registered accounting firm for fiscal year 2025, and a non-binding advisory vote approving named executive officer compensation.
The election of the directors saw a majority of votes cast in favor, with a significant number of broker non-votes. The ratification of the accounting firm was passed with over 29 million votes in favor, and the executive compensation resolution was approved with over 16 million votes in favor.
The details of the Equity Incentive Plan were previously described in the company’s proxy statement filed on April 8, 2025. The full text of the plan was included as an appendix to the proxy statement.
This news comes from a filing by the Delaware-incorporated company and reflects the decisions made by shareholders regarding the company’s governance and compensation plans. The information in this article is based on the company’s SEC filing.
In other recent news, Capricor Therapeutics reported a significant earnings miss for the first quarter of 2025, with earnings per share at -$0.53, falling short of the forecasted -$0.32. The company also reported zero revenue for the quarter, a decrease from $4.9 million in the same period last year. Despite these setbacks, Capricor maintains a strong cash position of $144.8 million as of March 31, 2025. Analysts from Roth/MKM have shown confidence in Capricor’s future prospects, initiating coverage with a Buy rating and a 12-month price target of $31. This optimism is largely based on the potential of Capricor’s product, deramiocel™, which is expected to launch in the U.S. in late 2025. The company anticipates significant financial incentives upon approval of deramiocel™, including a Priority Review Voucher and an $80 million milestone payment. Capricor is also preparing for a critical FDA Advisory Committee meeting, with potential approval for its DMD cardiomyopathy therapy expected in late 2025. Additionally, Capricor is exploring market opportunities in Europe and Japan while planning to expand its manufacturing capabilities by 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.